235 related articles for article (PubMed ID: 9164416)
1. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.
Borin MT; Chambers JH; Carel BJ; Gagnon S; Freimuth WW
Clin Pharmacol Ther; 1997 May; 61(5):544-53. PubMed ID: 9164416
[TBL] [Abstract][Full Text] [Related]
2. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
Cheng CL; Smith DE; Carver PL; Cox SR; Watkins PB; Blake DS; Kauffman CA; Meyer KM; Amidon GL; Stetson PL
Clin Pharmacol Ther; 1997 May; 61(5):531-43. PubMed ID: 9164415
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients.
Borin MT; Chambers JH; Carel BJ; Freimuth WW; Aksentijevich S; Piergies AA
Antiviral Res; 1997 Jun; 35(1):53-63. PubMed ID: 9224961
[TBL] [Abstract][Full Text] [Related]
4. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.
Borin MT; Cox SR; Herman BD; Carel BJ; Anderson RD; Freimuth WW
Antimicrob Agents Chemother; 1997 Sep; 41(9):1892-7. PubMed ID: 9303380
[TBL] [Abstract][Full Text] [Related]
5. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
6. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
7. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice.
Chang M; Sood VK; Wilson GJ; Kloosterman DA; Sanders PE; Hauer MJ; Zhang W; Branstetter DG
Drug Metab Dispos; 1997 Jul; 25(7):828-39. PubMed ID: 9224777
[TBL] [Abstract][Full Text] [Related]
9. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.
Cato A; Cavanaugh J; Shi H; Hsu A; Leonard J; Granneman R
Clin Pharmacol Ther; 1998 Apr; 63(4):414-21. PubMed ID: 9585795
[TBL] [Abstract][Full Text] [Related]
10. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I.
Keung A; Reith K; Eller MG; McKenzie KA; Cheng L; Weir SJ
Int J Tuberc Lung Dis; 1999 May; 3(5):426-36. PubMed ID: 10331733
[TBL] [Abstract][Full Text] [Related]
11. Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys.
Chang M; Sood VK; Kloosterman DA; Hauer MJ; Fagerness PE; Sanders PE; Vrbanac JJ
Drug Metab Dispos; 1997 Jul; 25(7):814-27. PubMed ID: 9224776
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats.
Chang M; Sood VK; Wilson GJ; Kloosterman DA; Sanders PE; Hauer MJ; Fagerness PE
Drug Metab Dispos; 1997 Feb; 25(2):228-42. PubMed ID: 9029054
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Ushiama H; Echizen H; Nachi S; Ohnishi A
Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
[TBL] [Abstract][Full Text] [Related]
14. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.
Tran JQ; Petersen C; Garrett M; Hee B; Kerr BM
Clin Pharmacol Ther; 2002 Dec; 72(6):615-26. PubMed ID: 12496743
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.
Droste JA; Verweij-van Wissen CP; Kearney BP; Buffels R; Vanhorssen PJ; Hekster YA; Burger DM
Antimicrob Agents Chemother; 2005 Feb; 49(2):680-4. PubMed ID: 15673751
[TBL] [Abstract][Full Text] [Related]
17. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.
Farid NA; Jakubowski JA; Payne CD; Li YG; Jin Y; Ernest II CS; Winters KJ; Brandt JT; Salazar DE; Small DS
Curr Med Res Opin; 2009 Aug; 25(8):1821-9. PubMed ID: 19530977
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations.
Kovacs SJ; Martin DE; Everitt DE; Patterson SD; Jorkasky DK
Clin Pharmacol Ther; 1998 Jun; 63(6):617-22. PubMed ID: 9663175
[TBL] [Abstract][Full Text] [Related]
19. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.
Park JY; Kim KA; Kang MH; Kim SL; Shin JG
Clin Pharmacol Ther; 2004 Mar; 75(3):157-62. PubMed ID: 15001966
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.
Gallicano K; Khaliq Y; Carignan G; Tseng A; Walmsley S; Cameron DW
Clin Pharmacol Ther; 2001 Aug; 70(2):149-58. PubMed ID: 11503009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
